Observational analysis achieved high early remission in newly diagnosed AML and MDS patients, suggesting non-intensive chemotherapy may improve outcomes.
Key Points
High early remission rates observed in newly diagnosed patients with AML and MDS.
After two weeks, 68.9% of patients achieved complete remission, indicating promising efficacy.
Treatment involved non-intensive chemotherapy with selinexor, azacitidine, and venetoclax tailored to early response.
Findings highlight the potential of selinexor as a viable treatment approach for patients unfit for intensive therapy.